Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808043 | 0.85 | MRGPRX1 (0.53) | MRGPRX1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL1809103 | 0.82 | MRGPRX1 (0.49) | MRGPRX1MAPTLMNAHSD17B10MEN1 | |
| SCHEMBL11314652 | 0.81 | TSHR (0.51) | MRGPRX1MAPTLMNAHSD17B10ALDH1A1 | |
| SCHEMBL22853109 | 0.79 | MRGPRX1 (0.56) | MRGPRX1MAPTLMNAKDM4EHSD17B10 | |
| SCHEMBL30294316 | 0.79 | MRGPRX1 (0.56) | MRGPRX1MAPTLMNAKDM4EHSD17B10 | |
| SCHEMBL30294699 | 0.77 | MRGPRX1 (0.54) | MRGPRX1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL22853077 | 0.77 | MRGPRX1 (0.54) | MRGPRX1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL12165544 | 0.76 | MRGPRX1 (0.51) | MRGPRX1MAPTLMNAALDH1A1MEN1 | |
| SCHEMBL28535658 | 0.76 | ALDH1A1 (0.54) | MAPTLMNAKDM4EALDH1A1MEN1 | |
| SCHEMBL11822995 | 0.76 | KDM4E (0.63) | MAPTLMNAKDM4EHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | PNMT, AADAT, INMT | MRGPRX1 924/4885MAPT 621/4885LMNA 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.